KEYMED BIO-B News

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTNMPA APPROVED THE SNDA OF STAPOKIBARTFOR THE TREATMENT OF CHRONIC RHINOSINUSITISWITH NASAL POLYPOSIS

Dec 23 03:30 ET

KEYMED BIO-B: CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Dec 16 08:00 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTTHE LATEST DATA FROM THE PHASE I/II CLINICAL STUDY OFCM336 AT THE 66TH AMERICAN SOCIETY OF HEMATOLOGY(ASH) ANNUAL MEETING BY WAY OF A POSTER

Dec 9 03:30 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024

Dec 3 03:34 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTEXCLUSIVE LICENSE AGREEMENT FOR CM336

Nov 17 05:04 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024

Nov 1 04:36 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024

Oct 2 04:34 ET

KEYMED BIO-B: 2024 INTERIM REPORT

Sep 23 09:01 ET

KEYMED BIO-B: INSIDE INFORMATION ANNOUNCEMENTSTAPOKIBART WAS GRANTED MARKETING APPROVAL FROMNATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR THETREATMENT OF MODERATE-TO-SEVEREATOPIC DERMATITIS IN ADULTS

Sep 12 06:15 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024

Sep 2 04:54 ET

KEYMED BIO-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024

Aug 27 06:23 ET

KEYMED BIO-B: DATE OF BOARD MEETING

Aug 15 04:35 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024

Aug 2 04:35 ET

KEYMED BIO-B: INSIDE INFORMATION -EXCLUSIVE LICENSE AGREEMENTFOR CM512 AND CM536

Jul 8 20:15 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024

Jul 4 05:01 ET

KEYMED BIO-B: SIXTH AMENDED AND RESTATEDMEMORANDUM AND ARTICLES OF ASSOCIATION

Jun 25 08:14 ET

KEYMED BIO-B: POLL RESULTS OF THE ANNUAL GENERALMEETING HELD ON JUNE 25, 2024

Jun 25 08:06 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENT RESULTS FROM AN EXPLORATORY CLINICAL STUDY OF CM313 IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA WERE RECENTLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE

Jun 19 20:15 ET

KEYMED BIO-B: VOLUNTARY ANNOUNCEMENTNEW DRUG APPLICATION OF STAPOKIBART INJECTION FORTHE TREATMENT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPSACCEPTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Jun 6 20:00 ET

KEYMED BIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024

Jun 5 04:43 ET